

AngioDynamics Launches Micro-Introducer Kits with a New Stiffened Introducer Option

New Options Provide Physicians with Comprehensive Product Line from Single Source

QUEENSBURY, N.Y., Dec 30, 2009 (BUSINESS WIRE) -- [AngioDynamics](#) (NASDAQ:ANGO) today announced the launch of a new family of micro-introducer kits, featuring a stiffened introducer option.

AngioDynamics' micro-introducers allow physicians to perform percutaneous introduction of a guidewire or catheter into the peripheral vasculature during minimally invasive percutaneous procedures, utilizing a 21 gauge needle.

"The new family of micro-introducer kits with the stiffened introducer option was developed based on the physician feedback we continue to draw on to spur innovation," said Shawn McCarthy, Senior Vice President and General Manager of the Peripheral Vascular business unit. "Our broad range of kits gives physicians a comprehensive set of options to treat their patients and allows healthcare institutions to source all micro-introducer needs from a reliable and trusted provider."

The new kits include a needle, micro-introducer, and .018" guidewire. They feature stiffened and standard introducer options with various needle configurations, including super-sharp needles and echogenic tip options. The guidewire has a range of configurations, including stainless steel, nitinol, and tungsten; tungsten-coiled tips allow for enhanced radiopacity while the nitinol wire helps resist against kinking.

The micro-introducer kits are available in 4 and 5 French sizes, in both standard and stiffened configurations, which facilitate smooth entry into difficult vessels. All feature a quarter-twist cam connection, which verifies a secure lock, and seamless dilator-to-sheath transitions.

For additional information on the new micro-introducer kits, visit the AngioDynamics web site at www.angiodynamics.com.

About AngioDynamics

AngioDynamics is a leading provider of innovative medical devices used by interventional radiologists, surgeons and other physicians for the minimally-invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency and irreversible electroporation ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.AngioDynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics' expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "potential," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ from the Company's expectations. Factors that may affect the actual results achieved by the Company include, without limitation, the ability of the Company to develop its existing and new products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of the Company to execute its leadership development plan and integrate purchased businesses, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2009. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

SOURCE: AngioDynamics, Inc.

[AngioDynamics, Inc.](#)

D. Joseph Gersuk, CFO, 800-772-6446 ext. 1608

jgersuk@AngioDynamics.com

or

EVC Group, Inc.

Investor Relations:

Doug Sherk or Jenifer Kirtland, 415-896-2005

dsherkevcgroup.com

jkirtland@evcgroup.com

Media:

Chris Gale or Steve DiMattia, 646-201-5431

cgale@evcgroup.com

sdimattia@evcgroup.com

Copyright Business Wire 2009